Novel Biomarkers in Neurodegenerative Disorders
A special issue of Metabolites (ISSN 2218-1989). This special issue belongs to the section "Endocrinology and Clinical Metabolic Research".
Deadline for manuscript submissions: closed (15 December 2022) | Viewed by 2416
Special Issue Editors
2. Neuroscience Graduate Program, University of Southern California, Los Angeles, CA, USA
Interests: dementia; stroke; Alzheimer’s disease; blood–brain barrier; cerebrovasculature; perivascular spaces; magnetic resonance imaging
Special Issues, Collections and Topics in MDPI journals
Interests: neuropharmacology; psychoneuroimmunoendocrinology; environmental neuroscience; glial cells; metabolomic
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
In the last decade, the advancement in neuroimaging and omics fields, including metabolomics, genomics, transcriptomics, proteomics, lipidomics and radiomics, has made it possible to significantly increase the knowledge about the biological mechanisms underlying healthy aging and neurodegenerative diseases such as Alzheimer’s disease and other types of dementia. In particular, the integration of multiple omics approaches made it possible to gain insights into the metabolic processes characterizing specific stages of the investigated diseases, and how they are affected by certain treatments. From a clinical perspective, this knowledge is particularly important not only for the development of strategies for the treatment and prevention of these pathologies, but also for the identification of biomarkers for neurodegenerative diseases, which may ultimately lead to the optimization of the current diagnostic frameworks and clinical management of patients.
This Special Issue aims to include preclinical, population-based, and clinical studies that investigate biological processes underlying neurodegenerative diseases for the identification of novel biomarkers. Investigations integrating different types of technologies with one or more omics approaches are particularly encouraged. Methodological articles presenting novel strategies for biomarker discoveries and validation will also be highly considered.
Dr. Giuseppe Barisano
Dr. Silvia Alboni
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Metabolites is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- neurodegenerative diseases
- Alzheimer’s disease
- dementia
- Parkinson’s disease
- neuroimaging
- metabolomics
- proteomics
- lipidomics
- transcriptomics
- genomics
